Invitae Corporation Stock News

Invitae's revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into profitability.

While penny stocks offer high potential gains, they are among the riskiest sub-$5 investments an investor can make. The low stock price penny stocks offer often reflects weak business models, high deb

- Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care - - These studies combined with new digital tools aim to increase access and frequency of heredit

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization.

Invitae (NYSE: NVTA ) stock is on the rise Monday despite a lack of news from the medical genetics company this morning. There haven't been any new press releases or filings with the Securities and Ex

The genetic testing company is reducing costs to improve margins.

Invitae has struggled to turn rising revenue into profit. Last year, the company launched a strategic plan to pave the way to positive cash flow and is making some progress.

Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.

Invitae announced an agreement to exchange old notes for new notes plus more than 15.8 million new shares. Website StockNews.com also downgraded the stock from hold to sell.

The innovative medical services company is making adjustments to improve the bottom line.

Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.

Stock market analysts have conflicting opinions about the market value of this genetic testing business. Worth more than $10 billion at its peak, beaten-down Invitae could provide huge returns if it c

Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Popular investment manager Cathie Wood is known for investing in innovative growth stocks.

Emergent BioSolutions just got a nod from regulators for over-the-counter use of a product to fight opioid overdose. Invitae is making progress on a plan to reach positive cash flow.